We continue to reflect on Capgemini’s acquisition of Altran.
Altran achieved in Q1 2019 a CC/CS growth yoy of 8.1% despite the impact of the decline in revenues of Aricent (-2% at CC/CS) and its cyber-attack (impacting the revenue growth of Altran by 200 bps).
Altran has phased out the Aricent brand in North America and now trades under the Altran brand. The company highlights it now has three primary brands: Aricent for its core ER&D services, Cambridge Consultants for its “innovation consulting” capabilities, and Frog for product design
Altran had a yoy CC/CS revenue growth of +10.4% in Q3 2018, with revenues reaching EUR 731m (USD 933m). Growth was broad-based with all major business units back to solid growth. As announced, France, still Altran’s largest geography was
There is a bit of irony about the performance of the stock of Altran on Thursday: Altran announced that it had found no further forgery in the accounts of Aricent. The company provided more light on how and where
Altran has unveiled its much-awaited 2022 strategic plan, called The High Road. Contrary to the previous strategic Ignition 2022, which was about about reinvention and business model transformation, this one strategic plan is about integration of existing assets, about
Altran, Alten, and Akka have in the past year accelerated their expansion into the US ER&D services market. It is striking to see how they have taken different routes. Altran swallows Aricent and gets scale in the US telecom
ERDservices is pleased to announce its ranking of the fastest-growing ER&D service vendors in CY 2017. Note that this ranking is based on reported numbers (and not on CC or CC/CS numbers). More about the methodology below the chart.
Altran released its last financial results before the integration of Aricent. The company had in 2017 revenues of EUR 2,282m, up 10%, and up 4.8% at CC/CS. Its adjusted EBIT margin accounted for 10.8% of revenues, its highest margin
Several industry observers, and even, the CEO of Altran, Dominique Cerutti, have predicted that following the Altran Aricent move, the ER&D industry would accelerate its industry consolidation. Is this right? The USD 2bn Aricent acquisition certainly is the largest